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Abstract
Rationale Antipsychotic affinity for the histamine H1
receptor and the muscarinic M3 receptor have been
associated with the side effects weight gain, and develop-
ment of diabetes, respectively.
Objectives We investigated polymorphisms of the hista-
mine H1 (HRH1) and muscarinic acetylcholine receptor M3
(CHRM3) receptor genes for an association with body mass
index (BMI) and glycated hemoglobin (HbA1c).
Methods We included 430 Caucasian patients with a non-
affective psychotic disorder using antipsychotics for at least
3 months. Primary endpoints of the study were cross-
sectionally measured BMI and HbA1c; secondary end-
points were obesity and hyperglycaemia. Two single-
nucleotide polymorphisms (SNPs) in the HRH1 gene,
rs346074 and rs346070, and one SNP in the CHRM3 gene,
rs3738435, were genotyped. Our primary hypothesis in this
study was an interaction between genotype on BMI and
antipsychotic affinity for the H1 and M3 receptor.
Results A significant association of interaction between
haplotype rs346074–rs346070 and BMI (p value 0.025)
and obesity (p value 0.005) in patients using high-H1
affinity antipsychotics versus patients using low-H1 affinity
antipsychotics was found. There was no association of
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DOI 10.1007/s00213-011-2211-xCHRM3 gene variant rs3738435 with BMI, and we
observed no association with HbA1c or hyperglycaemia in
any of the variants.
Conclusions This study, for the first time, demonstrates a
significant association between HRH1 variants and BMI in
patients with a psychotic disorder using antipsychotics. In
future, genotyping of HRH1 variants may help predicting
weight gain in patients using antipsychotics.
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Introduction
The majority of patients with schizophrenia or other
psychotic disorder use antipsychotic medication. Antipsy-
chotic treatment, especially the use of clozapine and
olanzapine, increases the risk of developing obesity
(Allison et al. 1999; Lieberman et al. 2005; Parsons et al.
2009) and type 2 diabetes mellitus (T2DM) (Leslie and
Rosenheck. 2004; Holt et al. 2005; Lieberman et al. 2005;
Miller et al. 2005b; Newcomer. 2005; Gianfrancesco et al.
2006; Nasrallah. 2006). The underlying mechanisms of
antipsychotic-induced weight gain and diabetes mellitus
are unknown, and may involve different pathways. As in
the general population, obesity may have an unfavorable
impact on glucose homeostasis in patients using anti-
psychotics. However, several studies have shown elevat-
ed serum insulin levels following atypical antipsychotic
medication independent of body mass index (BMI)
(Melkersson et al. 2000;A r r a n ze ta l .2004; Henderson
et al. 2005). This finding suggests that antipsychotics may
directly affect glucose homeostasis by mechanisms other
than by weight gain alone. There is also a considerable
variability among users of the same antipsychotic in weight
gain and T2DM (e.g., not all patients on clozapine ultimately
develop T2DM). It is plausible that this variability in patient
propensity to these side effects is determined by a combina-
tion of genetic and environmental factors.
Atypical antipsychotics may differ highly in their
affinities for the dopaminergic, serotonergic, histaminergic,
adrenergic, and muscarinic acetylcholine receptors (Roth et
al. 2004). Combining receptor affinities and clinical data,
several authors have concluded that histamine H1 antago-
nism showed the best correlation with drug-induced weight
gain and diabetes mellitus (Wirshing et al. 1999; Kroeze et
al. 2003; Matsui-Sakata et al. 2005). Likewise, antagonism
of the muscarine acetylcholine receptor was suggested to
play an important role, especially in the development of
diabetes mellitus (Matsui-Sakata et al. 2005; Silvestre and
Prous. 2005). Interactions with serotonergic (5-HT2C and
5-HT6) and adrenergic (alpha1A) receptors were also
significantly correlated with metabolic parameters (Kroeze
et al. 2003; Matsui-Sakata et al. 2005). To date, pharma-
cogenetic studies have shown the most consistent evidence
for polymorphisms in the 5-HT2C receptor and leptin genes
to be associated with antipsychotic-induced weight gain
(Reynolds et al. 2003; Ellingrod et al. 2005; Miller et al.
2005a; Templeman et al. 2005; Zhang et al. 2007; Kang et
al. 2008; Gregoor et al. 2009) and the metabolic syndrome
(Mulder et al. 2007a; Yevtushenko et al. 2008; Mulder et al.
2009; Risselada et al. 2010). So far, only two studies
(Basile et al. 2001; Hong et al. 2002) have reported on
histamine H1 polymorphisms and antipsychotic-induced
weight gain, both finding no association. Thus, the
contribution of genetic variations of the histamine and
muscarine acetylcholine receptors on the emergence of
weight gain and diabetes in antipsychotic-treated patients
remains to be elucidated.
The ventromedial hypothalamus and the paraventricular
nucleus of the brain, where H1 receptors are localized in
high density (Sakata et al. 1995), play a central role in the
development of obesity by regulating energy expenditure
and food intake (Masaki et al. 2004). Clozapine, olanza-
pine, and quetiapine exhibit the highest affinities for the H1
receptor, whereas risperidone and aripiprazole exhibit
lower, and ziprasidone and haloperidol exhibit hardly any
affinity towards the H1 receptor (Roth et al. 2004;
Nasrallah. 2008). Clozapine and olanzapine are also known
to induce most weight gain, followed by quetiapine and
risperidone. Aripiprazole, ziprasidone, and haloperidol are
known to cause little or no weight gain at all (Wirshing et
al. 1999; Nasrallah. 2008). Tricyclic antidepressants with a
high antihistaminergic effect (e.g. amitriptyline) are found
to induce weight gain as well (Zimmermann et al. 2003).
The histamine H1 receptor may therefore play a role in the
etiology of medication-induced weight gain.
The M3 receptor is expressed on pancreatic β cells.
These receptors seem to play a critical role in regulating
insulin release and glucose homeostasis (Gautam et al.
2006). Impaired glucose tolerance and reduced levels of
insulin were found in mice with targeted deletions in the
CHRM3 gene (Gautam et al. 2006). This might indicate that
antagonism of the β-cell M3 receptor leads to a higher risk
of hyperglycemia and developing diabetes in humans.
Olanzapine and clozapine, which have the highest binding
affinities with the M3 receptor, have been associated with
highest risk of developing T2DM (Citrome et al. 2004;
Leslie and Rosenheck. 2004; Holt et al. 2005; Newcomer.
2005) and higher levels of glycated hemoglobin (HBA1c)
and blood glucose (Lieberman et al. 2005; Gianfrancesco et
al. 2006; Nasrallah. 2008). Risperidone, quetiapine, zipra-
sidone, haloperidol, and aripiprazole have weak to absent
M3 receptor antagonistic activity (Roth et al. 2004;
258 Psychopharmacology (2011) 216:257–265Nasrallah. 2008) and are associated with lower levels of
HbA1c and blood glucose in patients (Lieberman et al.
2005; Nasrallah. 2008).
Out of the known H1 receptor gene (HRH1) splice
variants, we studied two polymorphisms in the B/K variant,
which is by far the most prevalent (95%) in the brain (Swan
et al. 2006). Rs346070 is a single-nucleotide polymorphism
(SNP) and may be functional as it is located in the exonic
splicing enhancer region. SNP rs346074 is located in the
transcription factor binding sites of the HRH1 gene and
may thus affect transcription rates. The muscarinic acetyl-
choline receptor M3 (CHRM3) variant rs3738435 is located
in the 5′ untranslated region of the first exon. Its C allele
was found to be associated with increased risk of early-
onset type 2 diabetes and a reduced acute insulin response
in a family-based sample of Pima Indians (Guo et al. 2006).
This is, as far as we know, the first study to examine the
pharmacogenetics of genetic variations in genes encoding
for the histamine H1 (rs346074 and rs346070) and
muscarine M3 receptors (rs3738435) in relation to BMI
and HbA1c in Caucasian psychosis patients using anti-
psychotics. Our primary hypothesis in this cross-sectional
study is an interaction between the mentioned variations on
BMI and antipsychotic affinity for the H1 and M3 receptor.
Materials and methods
Setting
For this study, three similar psychiatric patient populations
from the Netherlands were pooled. The majority of patients
were from the ongoing ‘Pharmacotherapy Monitoring and
Outcome Survey’ (PHAMOUS). PHAMOUS is an initia-
tive from the Rob Giel Research centre, including three
Mental Health Care Institutions and the University Centre
of Psychiatry of Groningen. It combines a yearly somatic
screening with routine outcome assessment in patients
using antipsychotics included. Subjects included in this
study originated from the northern part of the Netherlands.
The two other study populations have been described in
detail elsewhere (Cohen et al. 2006; Mulder et al. 2007a;
Mulder et al. 2009). In brief, these populations consisted of
patients from a Department of Psychiatric Disorders of a
general hospital in the North of the Netherlands (Mulder et
al. 2007a; Mulder et al. 2009), and patients from a Mental
Health Care Organisation in the West of the Netherlands
(Cohen et al. 2006).
Design and patients
A cross-sectional design was used to assess the association
between the variants with BMI and HbA1c. Caucasian
patients (northern European ancestry) were eligible for
inclusion in this study when they met Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) criteria for a non-affective psychotic disorder
(schizophrenia, schizophreniform disorder, schizoaffective
disorder, delusional disorder, psychotic disorder not other-
wise specified (NOS)), were 18 years or older, and used one
or more antipsychotics for at least 3 months.
Outcome measures
The primary endpoints of the study were BMI, calculated as
body weight (kilogram) divided by height squared (square
meter), and the proportion glycated hemoglobin HbA1c
(percent). BMI was measured in all patients; HbA1c values
were available only in the PHAMOUS population.
Determinants
Primary determinants were the genotypes of the two SNPs
in the HRH1 gene, rs346074 (G/A) and rs346070 (C/T),
and one SNP in the CHRM3 gene, rs3738435 (C/T). Other
clinical and demographic (co)variables that were measured
in the study were gender, age, patient population, DSM-IV-
diagnosis, and antipsychotic medication used at the day of
assessment.
Genotyping
The study protocol was approved by the local university
hospital medical ethics committee and all participants gave
their written informed consent. Genomic DNA was
extracted from EDTA whole blood according to standard
protocols. Genotyping of rs3738435, rs346070, and
rs346074 was conducted blind to the clinical status of the
patients. Fluorogenic 5′-exonuclease TaqMan® assays were
applied for the genotyping (Made-To-Order assays obtained
from Applied Biosystems; C2747428510, C60474110, and
C2685588510, respectively). Genotyping success rates
were 99% for rs346074 and 100% for rs346070 and
rs3738435.
Statistical analysis
To compare BMI and HbA1c values among various users
of antipsychotics (i.e., BMI in users of clozapine versus
olanzapine versus risperidon versus aripiprazole versus
quetiapine versus users of more than one antipsychotic)
and between patients using typical versus atypical anti-
psychotics we applied analysis of variance (ANOVA) and
Student"s t test, respectively. We used linear regression to
explore the relationship of BMI and HbA1c with the
independent variables age, gender, and patient population.
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culated by a χ
2 test with 1df. We initially considered an
additive model for rs346074 (HRH1), and, due to the low
numbers of the recessive genotype, a dominant model for
rs3738435 (CHRM3) and rs346070 (HRH1).
We first compared demographic characteristics between
the genotypes of the three variants. To test our primary
hypothesis, we applied linear regression to test whether
genotype in users of high-affinity antipsychotics has a
significantly different outcome on BMI and HbA1c than in
users of low-affinity antipsychotics. We used the interaction
term affinity x genotype in our model to test this
association, where affinity was coded as 1 or 0 when the
patient used a high- or a low-affinity antipsychotic,
respectively. A pKi > 7 defined a high-affinity antipsychot-
ic for a certain receptor (Nasrallah. 2008), the other
antipsychotics were considered having a low affinity. We
adjusted for age, gender, and patient population in our
analyses. Similarly, logistic regression was used to analyze
the associations with obesity (BMI > 30 kg/m
2)a n d
hyperglycemia (HbA1c ≥ 6.1% or the use of antidiabetics).
Additionally, for the two HRH1 variants haplotype analysis
using the haplotype trend regression approach (Zaykin et al.
2002) was performed, with haplotypes inferred by the
software package PHASE (Stephens et al. 2001; Stephens
and Donnelly. 2003). Pairwise linkage disequilibirum (LD)
was tested by calculating D′, as well as r
2. All of the
analyses were performed using standard software (SPSS
16.0 for Windows). The level of significance was set at
0.05, two-sided.
Results
Subjects
A total of 430 subjects met the inclusion criteria. Table 1
presents their demographic, genetic, and clinical character-
istics. Approximately 95% of the patients had a diagnosis
within the schizophrenia spectrum, the other patients had a
psychotic disorder not otherwise specified (NOS).
Medication
Patients used monotherapy clozapine (21.9%), olanzapine
(22.6%) or risperidon (22.1%), aripiprazole (2.3%), quetia-
pine (4.2%), typical antipsychotics (14.4%), or had a
combination of more than one antipsychotic (12.6%). No
substantial differences in BMI (range 27.4–29.3 kg/m
2)
were found between users of the various antipsychotics
(p value ANOVA 0.58) or between different diagnoses.
HbA1c values (range 5.5–6.8%) were significantly differ-
Characteristic Total study sample (n = 430)
Age, mean (range) 38.4 (18–69)
Gender
•Male 290 (67%)
•Female 140 (33%)
DSMIV-Diagnosis
•Schizophrenia 333 (77%)
•Schizoaffective disorder 77 (18%)
•Psychotic disorder NOS 20 (5%)
Antipsychotic medication
•Typical 68 (16%)
•Atypical 362 (84%)
BMI (kg/m
2), mean (SD) 28.0 (5.2)
Weight category
•Non-obese (BMI < 25) 135 (31%)
•Overweight (BMI 25-30) 157 (37%)
•Obesity (BMI > 30) 138 (32%)
HbA1c (%) (n=221)
•Mean (SD) 5.78 (1.25)
•Hyperglycaemia (HbA1c ≥ 6.1% or antidiabetic medication) 30 (14%)
Genotype rates
•HRH1 rs346074 (GG/GA/AA) 182/189/55
•HRH1 rs346070 (CC/CT/TT) 286/128/15
•CHRM3 rs3738435 (TT/TC/CC) 276/137/17
Table 1 Demographic, genetic,
and unadjusted clinical variables
of the total study sample
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0.033). Between users of typical and atypical antipsy-
chotics, no differences in BMI and HbA1c were found (p
value Student"s t test 0.93 and 0.82, respectively). Of all
antipsychotics used in our population, clozapine, olanza-
pine, and quetiapine were defined as high H1 receptor
affinity antipsychotics, and clozapine and olanzapine as
high M3 receptor affinity antipsychotics.
Association analyses
Genotype distributions were consistent with the Hardy–
Weinberg equilibrium (p values 0.59, 0.88, and 1.00 for
rs346074, rs346070, and rs3738435, respectively). Age
(increase of 0.055 kg/m
2 per year, p value 0.021) and
gender (increase of 2.97 kg/m
2 if female, p value <0.001)
were significantly associated with BMI. Patient population
was not associated with BMI. HbA1c was not associated
with patient population, age, or gender. Demographic
characteristics, DSM-IV-diagnosis, and antipsychotic dis-
tributions did not differ between genotype groups in all
three variants.
In Table 2 the genetic associations with BMI and obesity
are depicted. In users with antipsychotics with high H1
affinity, there was a non-significant increase in BMI per A
allele of rs346074 and per T allele of rs346070. An
opposite trend can be seen in users with a low H1 affinity
antipsychotic (see Fig. 1). The increased trend in BMI with
minor alleles of rs346074 and rs346070 in high H1 affinity
antipsychotic users was significantly different from the
decreased trend in BMI with minor alleles in low H1
affinity antipsychotic users. The interaction term genotype
x affinity tested significant when using an additive or
recessive model for the A allele of rs346074 (p values
Table 2 Mean BMI values and obesity proportions of genotype groups for SNPs rs346074, rs346070, and rs3738435 among 430 antipsychotic
users
Variables No. of patients Mean (SD)/proportion p value β genotype p value β interaction genotype x affinity
HRH1 rs346074 GG/GA/AA GG GA AA
BMI 182/189/55 28.0 (5.2) 27.8 (5.3) 28.5 (5.0) 0.93 0.046
High aff. 83/97/28 27.5 (4.2) 27.7 (5.3) 30.1 (5.3) 0.27
Low aff. 99/92/27 28.4 (5.9) 27.9 (5.2) 26.8 (4.0) 0.10
Obesity 182/189/55 34% 30% 31% 0.58 0.005
High aff. 83/97/28 25% 30% 46% 0.14
Low aff. 99/92/27 40% 30% 15% 0.015
HRH1 rs346070 CC/CT/TT CC CT TT
BMI 286/128/15 28.0 (5.1) 28.2 (5.6) 27.4 (4.8) 0.74 0.044
High aff. 139/58/12 27.6 (4.7) 29.0 (5.9) 28.5 (4.2) 0.10
Low aff. 147/70/3 28.4 (5.5) 27.5 (5.3) 22.9 (4.9) 0.22
Obesity 286/128/15 34% 29% 20% 0.22 0.009
High aff. 139/58/12 28% 38% 25% 0.36
Low aff. 147/70/3 39% 21% 0% 0.006
CHRM3 rs3738435 TT/TC/CC TT TC CC
BMI 276/137/17 28.0 (5.2) 27.6 (5.2) 30.4 (5.5) 0.60 0.88
High aff. 127/57/7 27.8 (4.9) 27.8 (4.9) 30.7 (6.1) 0.33
Low aff. 149/80/10 28.3 (5.5) 27.5 (5.4) 30.2 (5.3) 0.90
Obesity 276/137/17 31% 32% 53% 0.15 0.56
High aff. 127/57/7 28% 32% 57% 0.16
Low aff. 149/80/10 34% 33% 50% 0.56
BMI (kg/m
2, mean and standard deviation) and obesity (%) are given per genotype group, separated in users of antipsychotics with low and high affinity
for the histamine H1 receptor (in rs346074 and rs346070 high affinity clozapine, olanzapine, and quetiapine) and the muscarine M3 receptor (in rs3738435
high affinity clozapine and olanzapine).
p values are given for (1) the β of the variable genotype in linear and logistic regression, and (2) the β of the interaction term genotype x affinity
in linear and logistic regression
All results are adjusted for age, gender, and population group
Genotype was tested additive in rs346074, and dominant for the minor allele in rs346070 and rs3738435
Significant p values are shown in bold
Psychopharmacology (2011) 216:257–265 2610.046 and 0.033, respectively), and when using a dominant
model for the T allele of rs346070 (p value 0.044).
Logistic regression showed similar results regarding
genotype and obesity, but even stronger and more significant.
The interaction terms genotype x affinity for rs346074 (OR
2.80, 95% CI 1.23–6.37, p value 0.015) and rs346070 (OR
2.51, 95% CI 1.33–4.74, p value 0.005) were both
significant. Thus, for a patient, there is a more than two-
and-a-half times higher risk of obesity per minor allele of
rs346074 when having a high H1 affinity antipsychotic as
compared to when having a low H1 affinity antipsychotic.
The two HRH1 SNPs were found to be in substantial LD
(D′=1.00, r
2=0.42). Haplotype analyses of the two poly-
morphisms showed similar opposite effects of haplotype on
BMI and obesity in low and high H1 affinity antipsychotic
users (see Table 3). For each AT-haplotype, having a high
H1 affinity antipsychotic means a more than three times
higher risk of obesity (p value 0.005) compared to the
reference haplotype G-C, than when having a low H1
affinity antipsychotic.
In the total sample of antipsychotic users, CHRM3
rs3738435 had no effect on BMI. There were no differences
in genotype effect on BMI between users of antipsychotics
with high and low affinity for the M3 receptor. None of the
three SNPs showed any association with HbA1c or hyper-
glycaemia (see supplemental Table 1).
Discussion
To the bestof our knowledge, this is the first study to examine
the pharmacogenetics of histamine H1 (rs346074 and
rs346070) and muscarine M3 (rs3738435) receptor variants
in relationship to weight gain and hyperglycaemia as proxied
by BMI and HbA1c in Caucasian psychosis patients on
antipsychotics. We demonstrated significant associations
between the HRH1 gene variants rs346070 and rs346074
and BMI in Caucasian patients with a psychotic disorder
when comparing users of high H1 affinity antipsychotics
with low H1 affinity antipsychotics. We found no association
between the CHRM3 gene variant rs3738435 and BMI. We
observed no association with HbA1c in any of the variants.
Although it has been proposed that histamine H1 receptor
antagonism causes weight gain (Kroeze et al. 2003;M a t s u i -
Sakata et al. 2005), earlier studies on other histamine H1
receptor variants showed no relationship with clozapine-
induced weight gain (Basile et al. 2001;H o n ge ta l .2002). Of
note, post-hoc analysis in our study showed similar direction
and effect size of the risk alleles on BMI in all three high H1
affinity antipsychotics studied (clozapine, olanzapine, and
quetiapine), emphasizing the role of the histamine receptor.
Regarding the metabolic consequences of antipsychotic
treatment, several receptors other than the H1 receptor are
of importance (Reynolds and Kirk. 2010), especially the 5-
HT2C receptor. Previously, we have shown a significant
association between 5-HT2C polymorphism rs1414334 and
obesity (Mulder et al. 2007b) and the metabolic syndrome
(Mulder et al. 2007a; Mulder et al. 2009; Risselada et al.
2010). The association with obesity of this polymorphism
also tested significant in the present population (data not
shown). We additionally included this polymorphism as a
covariate in our regression analysis on obesity. This did not
alter the results of the H1 polymorphisms on obesity,
implying a 5-HT2C rs1414334 independent, additive effect
of our H1 polymorphisms.
Within the hypothalamus, histamine and the H1 receptor
are part of the leptin-signaling pathway (Sakata et al. 1988;
Fig. 1 HRH1 variants rs346074 and rs346070 and mean BMI values
in users of antipsychotics with and without affinity for the H1
receptor: a significant opposite effect can be seen between genotype
and BMI in users of antipsychotics with high versus low affinity for
the H1 receptor
262 Psychopharmacology (2011) 216:257–265Masaki et al. 2001). Leptin isan adipocyte-specific hormone
that regulates the mass of adipose tissue through hypotha-
lamic effects on satiety and energy expenditure (Forbes et al.
2001). Polymorphisms in the leptin and leptin receptor gene
have been associated with antipsychotic-induced weight gain
(Templeman et al. 2005; Zhang et al. 2007;K a n ge ta l .
2008; Gregoor et al. 2009). Templeman et al. (2005)
demonstrated that a genetic variation in the 5-HT2C receptor
resulted in different pre-treatment leptin levels. Of note, an
interaction between two polymorphisms in the 5-HT2C
receptor and leptin gene was showed to influence the risk of
metabolic disturbances during antipsychotic treatment (Yev-
tushenko et al. 2008). Futurestudiesinvestigatinggene–gene
interactions between histamine H1, 5-HT2C and leptin genes
may help unravel the exact role of the histamine system in
antipsychotic-induced weight gain.
Sincethebiologicalfunctionofthestudiedpolymorphisms
is unknown, one can only speculate about the observed
opposite genotype effects on BMI inlow and high H1affinity
antipsychotic users.Onepossibleexplanationmight layinthe
LD status of our polymorphisms with one or more other
functional polymorphisms. It might be that one of the
polymorphisms in LD with our polymorphisms has a large,
H1 affinity antipsychotic-induced effect, while another
polymorphism in LD has a moderate opposite antipsychotic-
independent effect. If our results are true-positive associa-
tions, then high H1 affinity antipsychotics should be avoided
when possible in patients with risk alleles. It would be
interesting for future studies to test whether these variants
could predict food intake or energy expenditure as well. This
might help to understand the pathways of histaminergic
mechanisms for atypical antipsychotic-induced weight gain.
Next to antipsychotics, several other risk factors for
hyperglycaemia are overrepresented in psychotic patients,
such as a positive family history, high BMI, and reduced
physical activity. It has been hypothesized that patients with
schizophrenia may already have β-cell defects prior to
antipsychotic treatment (Bergman and Ader. 2005). Since
several factors, involving multiple metabolic pathways, may
contribute to hyperglycaemia in psychosis patients, examin-
ing genetic associations with antipsychotic-induced alter-
ations in glucose homeostasis may be difficult to perform.
The present study has some limitations. First, we did not
have complete quantitative information on the cumulative
exposure to currently and previously used antipsychotics.
Therefore, the relationship between BMI and users of
antipsychotics with H1 affinity may be partly biased by
earlier use of a previous other antipsychotic. However,
since all patients used the antipsychotic for at least
3 months, we do not expect this limitation to be a serious
deficit. Second, since this study is cross-sectional, we did
not have information on BMI or HbA1c before antipsy-
chotic treatment was started, suggesting that results might
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Psychopharmacology (2011) 216:257–265 263reflect non-antipsychotic-mediated pathways. However, this
is very unlikely, since we decided to test the interaction
between genotype and antipsychotic affinity for the certain
receptor. We found significantly different genotype effects
on BMI values between users of antipsychotics with high
and low affinity for the H1 receptor. Since one would
expect genotype effect on baseline BMI values to be similar
between future users of low and high H1 affinity
antipsychotics, non-antipsychotic-mediated effects of geno-
type would not lead to differences in genotype effect on
BMI between users with high and low H1 affinity
antipsychotics. Also, genotype distributions did not differ
between users of low and high H1 affinity antipsychotics,
ruling out the possibility of confounding by indication
because of genotype. Despite its limitations this study has
also several merits. First, compared to previous studies, we
have a big sample size (more than 400 patients). Second,
we have a very homogeneous group of Caucasian patients
of Northern European ancestry, all diagnosed with a non-
affective psychosis.
In conclusion, the HRH1 gene haplotype consisting of
rs346074 and rs346070 might be associated with BMI and
obesity in patients using antipsychotics with high affinity
for the histamine H1 receptor. These findings need to be
replicated in independent samples. In none of the variants
an association with HbA1c or hyperglycaemia was found.
Genotyping for HRH1 variants may help predicting weight
gain in patients using atypical antipsychotics. Further
longitudinal studies are warranted to investigate the
potential role on BMI of the HRH1 gene.
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